Erick Wayne DeVinney sold $264k of AXGN
Chief Innovation Officer at Axogen, Inc.. 15,111 shares at an average of $17.50, traded Mar 19, 2025, filed Mar 19, 2025.
Score components
- +15RoleOfficer
- +13Trade size$264k at market
- 0Share of holdings soldSold 6.5% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -13.0%, 3m -48.1%, 6m -6.0%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000805928-25-000041, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 16, 2025 | MOption exercise Common Stock | +2,950 | $0.00 | $0 | 203,361 | Mar 19, 2025 |
| Mar 16, 2025 | MOption exercise Common Stock | +6,362 | $0.00 | $0 | 209,723 | Mar 19, 2025 |
| Mar 16, 2025 | MOption exercise Common Stock | +23,150 | $0.00 | $0 | 232,873 | Mar 19, 2025 |
| Mar 19, 2025 | SOpen-market sale Common Stock | -15,111 | $17.50 | $264k | 217,762 | Mar 19, 2025 |
| Mar 16, 2025 | MOption exercise Restricted Stock Unitsderivative | -2,950 | $0.00 | $0 | 0 | Mar 19, 2025 |
| Mar 16, 2025 | MOption exercise Restricted Stock Unitsderivative | -6,362 | $0.00 | $0 | 6,363 | Mar 19, 2025 |
| Mar 16, 2025 | MOption exercise Restricted Stock Unitsderivative | -23,150 | $0.00 | $0 | 23,150 | Mar 19, 2025 |
Related signals
Other insiders at Axogen, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 11Weak | Axogen, Inc. | Joseph A. Tyndall director | $174k 3,500 shares | -25% | |
| 20Weak | Axogen, Inc. | Amy McBride Wendell director | $647k 13,353 shares | -11% | |
| 40Moderate | Axogen, Inc. | Marc A Began EVP & General Counsel | $3.2M 67,500 shares | -57% | |
| 50Moderate | Axogen, Inc. | Kathy Johnson Weiler director | $641k 14,150 shares | -100% | |
| 23Weak | Axogen, Inc. | Amy McBride Wendell director | $70k 1,647 shares | -2% | |
| 41Moderate | Axogen, Inc. | Doris Quackenbush Sales VP | $169k 3,878 shares | -4% | |
| 28Weak | Axogen, Inc. | Lindsey Marie Hartley CFO | $46k 1,051 shares | -2% | |
| 41Moderate | Axogen, Inc. | Jens Kemp Chief Marketing Officer | $174k 4,000 shares | -5% | |
| 56Moderate | Axogen, Inc. | Kathy Johnson Weiler director | $721k 16,344 shares | -100% | |
| 53Moderate | Axogen, Inc. | John Johnson director | $478k 11,050 shares | -100% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.